Positive clinical data could drive near-term price momentum given the small market cap. Monitor for completion of Cohorts 6 and 7 and subsequent RP2D announcement, which may trigger further re-rating or partnership interest.
Price Chart
Executive Summary
Aptevo announced positive clinical data from its RAINIER frontline AML trial, showing an 81% remission rate (CR/CRi) and 87% clinical benefit rate in 31 evaluable patients, outperforming the historical VIALE-A benchmark of 66.4%. The Phase 1b dose-optimization trial remains on track for completion this year with Phase 2 dose selection.
Key Facts
- 81% remission rate (CR/CRi) in 31 evaluable frontline AML patients vs 66.4% historical benchmark (VIALE-A).
- 87% clinical benefit rate (CR/CRi/PR).
- 65% achieved complete remission (CR) vs 37% benchmark.
- No cytokine release syndrome reported; favorable safety profile.
- Trial on track to complete Phase 1b and select recommended Phase 2 dose this year.
Financial Impact
No financial figures provided; clinical data may support future partnership or funding opportunities for this $6M market cap biotech.
Risk Factors
- Small patient sample (N=31) and early-stage data may not replicate in larger trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-208958 |
| Document: apvo-ex99_1.htm | 0001193125-26-208958 |
| Document: 0001193125-26-208958-index-headers.html | 0001193125-26-208958 |
| Document: 0001193125-26-208958-index.html | 0001193125-26-208958 |
| Document: 0001193125-26-208958.txt | 0001193125-26-208958 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.73 | awaiting T+5 | — | $1.28 (−26.09%) |
Oct 23, 2026 4d ago | 8-K | $1.61 | awaiting T+5 | — | $1.28 (−20.50%) |
Oct 14, 2026 13d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.28 (−26.01%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.28 (−30.05%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.28 (−25.15%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.28 (+25.15%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.28 (−56.46%) |
Jul 27, 2026 13w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.28 (−69.60%) |
Jun 30, 2026 17w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.28 (−71.24%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.28 (−73.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers